Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (Non-GAAP)²
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals
Revenue
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin ²
R&D
R&D percent of Revenues
Adj. SG&A²
Adj. SG&A percent of Revenues³
Adj. EBITA 2,6
Depreciation
Stock Based Compensation
Adj. EBITDA 2,3,6
Adj. EBITDA Margin 2,6
Adj. Net Income 2,6
Adj EPS 3,4,6
3Q22
$598M
$172M
$172M
$942M
$570M
60.5%
$77M
8.2%
$360M
38.2%
$132M
$34M
$18M
$187M
3Q21
$605M
$173M
$171M
$949M
$585M
61.6%
$63M
6.6%
$348M
36.7%
$174M
$26M
$16M
$207M
21.8%
$124M
$0.35
Reported Change
(1%)
(1%)
1%
(1%)
(3%)
(110 bps)
(22%)
(3%)
(24%)
31%
13%
(10%)
19.9%
$107M
$0.31
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
3. Includes transactional FX and NCI.
BAUSCH + LOMB 4. On a proforma basis after giving effect to the IPO.
(14%)
Constant
Currency²
4%
7%
5%
5%
2%
(25%)
(10%)
(22%)
38%
13%
(15%)
(17%)
Organic Change²
4%
8%
5%
5%
+5% organic revenue growth 1,2,5
+$14M investment in R&D
during 3Q22 to expedite portfolio
advancement; YTD in R&D $229M,
-8% of revenue
Continued to maintain a disciplined
approach to cost management as
inflation pressure weighed on gross
margin
2021 results were not fully burdened
by all of the stand-up costs
associated with the separation
5. Organic revenue growth/change, a non-GAAP measure, is defined as change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
6. Prior to 2022, in calculating this non-GAAP measure/ratio, the Company had excluded expenses associated with acquired in-process research and development costs ("IPR&D"). Commencing in 2022, the Company no longer excludes acquired IPR&D in calculating these
amounts. The Company believes these costs are not material for the periods presented. See the Appendix for further information on this change.
10View entire presentation